Form 4: Co-Diagnostics Director James Nelson Converts Restricted Stock Units into Common Shares

Co-Diagnostics, Inc. Director James B. Nelson reported the acquisition of 48,334 shares of common stock through the vesting of restricted stock units on May 23, 2025, increasing his direct beneficial ownership.

Summary

• James B. Nelson, a Director of Co-Diagnostics, Inc. (CODX), reported a change in beneficial ownership via a Form 4 filing.
• On May 23, 2025, Mr. Nelson acquired 48,334 shares of Co-Diagnostics Common Stock at a price of $0.00 per share.
• This acquisition resulted from the vesting of previously awarded Restricted Stock Units (RSUs).
• Following this transaction, Mr. Nelson directly beneficially owns 211,667 shares of Common Stock.
• The transaction also reflects the conversion of 48,334 Restricted Stock Units into common shares.
• After the conversion, Mr. Nelson holds 103,333 Restricted Stock Units.
• The vested RSUs are part of awards granted on July 7, 2022 (70,000 RSUs), January 17, 2023 (40,000 RSUs), June 12, 2023 (70,000 RSUs), and April 26, 2024 (110,000 RSUs), all vesting in six equal installments every six months.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's a routine vesting event, it signifies a director's continued ownership and alignment with shareholder interests, without any negative implications from the filing itself.

Positives

• The acquisition of shares by a director, even through vesting, indicates continued alignment of management interests with shareholders.
• The vesting of RSUs is a pre-scheduled event, reflecting the company's ongoing equity compensation plan for its directors.

Risks

• Future vesting of RSUs could lead to potential dilution if the shares are sold into the market, although this is a standard aspect of equity compensation plans.

Future Outlook

The remaining 103,333 Restricted Stock Units held by Mr. Nelson are subject to future vesting schedules, which will result in additional common stock acquisitions over time, aligning with the terms of the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan.

Industry Context

This Form 4 filing is a routine disclosure for publicly traded companies, detailing changes in insider ownership. It reflects the standard practice of using equity compensation, such as Restricted Stock Units, to incentivize and retain directors and executives across various industries, including the diagnostics sector.

Stakeholder Impact

• Shareholders: The increase in a director's direct share ownership can be viewed positively as it aligns the director's interests with those of the shareholders. However, the eventual sale of these shares could lead to minor dilution.

Next Steps

• Future vesting events for the remaining 103,333 Restricted Stock Units held by James Nelson, as per the established vesting schedules.

Key Dates

Keywords

Co-Diagnostics, CODX, Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Compensation, Director, James B. Nelson, Beneficial Ownership